深圳开立生物医疗科技股份有限公司关于向2025年限制性股票与股票期权 激励计划激励对象授予限制性股票与股票期权的公告

Core Viewpoint - The company has approved a stock incentive plan for 2025, granting 1.914 million restricted stocks and 3.9678 million stock options to 405 incentive targets, aimed at enhancing employee motivation and aligning their interests with shareholders [2][19][24]. Summary by Sections Incentive Plan Overview - The incentive plan includes the grant of 1.914 million restricted stocks at a price of 15.93 CNY per share and 3.9678 million stock options at an exercise price of 31.86 CNY per option [2][3][21]. Grant Conditions - The grant date for the restricted stocks and stock options is set for October 16, 2025, with a total of 405 incentive targets, including directors, senior management, and key technical personnel [2][3][12]. Performance Assessment Requirements - The performance assessment for the incentive plan will cover the fiscal years 2025 to 2028, with specific annual performance targets established for each year [6][29]. Decision-Making Process - The decision-making process for the incentive plan involved multiple board meetings and approvals, culminating in a shareholder meeting on September 23, 2025, where the plan was ratified [9][10][12]. Compliance and Legal Review - The company has conducted a self-examination regarding insider trading and confirmed that no violations occurred prior to the public disclosure of the incentive plan [10][25]. Financial Impact - The estimated financial impact of the incentive plan on the company's net profit is expected to be minimal, with potential positive effects on operational efficiency and management motivation [30][31]. Legal Opinions - Legal opinions confirm that the incentive plan complies with relevant laws and regulations, and the granting conditions have been met [32][33].